Race Oncology will not be the company actually bringing Bisantrene back into final commercialisation and market as the very useful oncology drug that it has been already proven to be.
Proving up the formulation and proving potentials is important- inc FTO, and with Cardioprotection abilities , in addition to synergistic anti- cancer cells efficacy, and especially with the worlds predominate important existing oncology treatments in combination.
However- the actual full length of time to market I think will not be relevant for RAC shareholders.
RAC will not be here by then., perhaps many years before this.
Value realisation incrementally by the market, with data, and then more steadily as compelling value definitely for opportunity for a large pharmaceutical company to partner first or outright take over bisantrene as asset.
Ultimate development, as for with a significant resource once economic and fits in with plans of a major - be with a major global company.
Race Oncology will not be the company actually bringing...
-
- There are more pages in this discussion • 3,104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |